Login to Your Account

Gilenya Under Scrutiny for Rare Brain Infection

By Staff Reports

Thursday, August 29, 2013
The FDA is investigating an incidence of a rare brain infection in a European patient who developed progressive multifocal leukoencephalopathy (PML) after receiving Novartis AG’s multiple sclerosis (MS) drug Gilenya (fingolimod).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription